Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

医学 甘精胰岛素 磺酰脲 二甲双胍 2型糖尿病 内科学 兴奋剂 糖尿病 内分泌学 胰岛素 受体
作者
Stefano Del Prato,Steven E. Kahn,Imre J. Pavo,Govinda J. Weerakkody,Zhengyu Yang,John Doupis,Diego Aizenberg,Alan G Wynne,Jeffrey S. Riesmeyer,Robert J. Heine,Russell J. Wiese,Jochen Seufert
出处
期刊:Diabetologie Und Stoffwechsel [Georg Thieme Verlag]
卷期号:17 (S 01): S20-S21 被引量:13
标识
DOI:10.1055/s-0042-1746267
摘要

Background Efficacy and safety of novel dual GIP/GLP-1 receptor agonist tirzepatide versus insulin glargine was assessed in adults with type 2 diabetes inadequately controlled on metformin, sulfonylurea, and/or SGLT-2i and increased cardiovascular risk. Methods This open-label, Phase-3 study (N=1995, age 63.6y, HbA1c 8.52%, BMI 32.6kg/m2, cardiovascular disease 87%) randomised participants (1:1:1:3) to once-weekly tirzepatide (5, 10, 15mg) or titrated glargine (100U/mL). Study duration was up to 104 weeks. Primary endpoint was mean HbA1c change from baseline at 52 weeks. Safety was assessed over the full study period. Results At 52 weeks, tirzepatide was superior to glargine in HbA1c change from baseline; LSMean treatment differences were –0.80% (95% CI –0.92,–0.68) for 5mg, –0.99% (–1.11,–0.87) for 10mg, and –1.14% (–1.26,–1.02) for 15mg, all p<0.001. Tirzepatide 5, 10, and 15mg decreased body weight (LSMean -7.1, -9.5, and -11.7kg, respectively), while glargine increased weight (+1.9kg). Similar changes were observed to 104 weeks. Nausea (12–23%), diarrhoea (13–22%), decreased appetite (9–11%), and vomiting (5–9%) occurred more frequently with tirzepatide than glargine (2%, 4%, < 1%, and 2%, respectively); most were mild-to-moderate. Hypoglycaemia incidence (<54mg/dL or severe) was lower with tirzepatide (6–9%) than glargine (19%), particularly when not on sulfonylureas (1–3% vs. 16%). 109 participants had adjudicated MACE-4 (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) events; HR 0.74 (95% CI 0.51,1.08) for tirzepatide versus glargine. Conclusion HbA1c and body weight reductions with tirzepatide were clinically meaningful and superior to glargine, with no increased cardiovascular risk. Publication History Article published online: 26 May 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
暗潮雷场完成签到,获得积分10
刚刚
1秒前
聪明旭尧关注了科研通微信公众号
2秒前
2秒前
mochi发布了新的文献求助10
2秒前
星半夏完成签到,获得积分10
2秒前
嗯嗯哈哈完成签到,获得积分10
2秒前
2秒前
DarrenWu完成签到,获得积分10
2秒前
2秒前
HSora发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
mochi发布了新的文献求助10
4秒前
海水净化器完成签到 ,获得积分10
4秒前
萝卜花1968发布了新的文献求助10
5秒前
5秒前
科研通AI6.2的应助被Euler采纳,获得10
5秒前
Ava的应助被赫连烙采纳,获得10
5秒前
5秒前
5秒前
顾矜的应助被科研通管家采纳,获得10
5秒前
luobo发布了新的文献求助10
5秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
小蘑菇的应助被科研通管家采纳,获得10
5秒前
CodeCraft的应助被科研通管家采纳,获得10
5秒前
Lucas的应助被科研通管家采纳,获得10
6秒前
xxx发布了新的文献求助10
6秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
v0id的应助被科研通管家采纳,获得10
6秒前
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
fd的应助被tonyguo采纳,获得10
6秒前
共享精神的应助被科研通管家采纳,获得10
6秒前
稳重电话发布了新的文献求助10
6秒前
小二郎的应助被科研通管家采纳,获得10
6秒前
Hus11221完成签到,获得积分10
7秒前
7秒前
shi发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Spec 401: Standards for Jet Fuel Facility and Equipment Commissioning and Flushing at Airports, 2026.1 (Original Issue) 1000
Spec 103: Standard for Jet Fuel Quality Control at Airports, Revision 2026.1 1000
A Consideration on Use of Material Grades for Hull Structural Members Based on Fracture Toughness(Second Report) 500
AI Disclosure in Annual Reports: Evolution, Determinants, and Capital Market Participants’ Perceptions 500
5th World Conference on Detergents: Reinventing the Industry : Opportunities and Challenges 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8107684
求助须知:如何正确求助?哪些是违规求助? 9516049
关于积分的说明 21500710
捐赠科研通 7684112
什么是DOI,文献DOI怎么找? 3410571
关于科研通互助平台的介绍 2537858
邀请新用户注册赠送积分活动 2450417